Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials

Summary

GBI Research, the leading business intelligence provider, has released its latest research ‘Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials’ which provides an insight into different endpoints that are used in dermatological clinical trials. The report examines different aspects under clinical trial endpoints in dermatology such as analysis on major marketed drugs with an emphasis on safety and efficacy details, Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising drugs with more emphasis on safety, efficacy and clinical trial details, and terminated trial analysis. The company profiling highlights the marketed drugs in dermatology of different companies.

Dermatological disorders are diverse in clinical presentation, severity and epidemiology; and it affects all age groups of both sexes, however; children are more vulnerable and have been studied worldwide. This report details ‘Endpoints- Clinical Trials in Dermatology’, highlighting the five major dermatological disorders which are Alopecia, Acne Vulgaris, Herpes Zoster, Candidiasis and Atopic Dermatitis. The classification of the five major dermatological disorders is based upon the number of pipeline molecules present in Phase III stage of development. GBI Research analyses that safety and efficacy is the most widely used endpoint in majority of the clinical trials in dermatology. The primary and secondary endpoint that is mainly used to assess the majority of trial outcomes is safety.

Scope

- Data and analysis on the marketed products and analysis of their efficacy and safety details.
- Analysis of the five major dermatological disorders which include Alopecia, Acne Vulgaris, Herpes Zoster, Candidiasis and Atopic Dermatitis.
- Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry sponsored studies are included in the report.
- Analysis on most promising molecules of five major dermatological disorders with emphasis on their efficacy and safety details.
- Company profiling talks in detail about the companies, which are strong in the market.

Reasons to buy

- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.

Table Of Contents



List of Tables

1.1 List of Tables
Table 1: Endpoints - Clinical Trials in Dermatology, Alopecia, Primary and Secondary Endpoints of Phase III Molecules , Global, 2010 16
Table 2: Endpoints - Clinical Trials in Dermatology, Alopecia, Primary and Secondary Endpoints of Phase II Molecules, Global, 2010 18
Table 3: Endpoints - Clinical Trials in Dermatology, Alopecia, Primary and Secondary Endpoints of Discontinued Molecules, Global, 2010 19
Table 4: Endpoints - Clinical Trials in Dermatology, Candidiasis, Primary and Secondary Endpoints of Phase III Molecules , Global, 2010 31
Table 5: Endpoints - Clinical Trials in Dermatology, Candidiasis, Primary and Secondary Endpoints of Phase II Molecules , Global, 2010 36
Table 6: Endpoints - Clinical Trials in Dermatology, Candidiasis, Primary and Secondary Endpoints of Discontinued Molecules, Global, 2010 36
Table 7: Endpoints - Clinical Trials in Dermatology, Atopic Dermatitis, Primary and Secondary Endpoints of Phase III Molecules , Global, 2010 45
Table 8: Endpoints - Clinical Trials in Dermatology, Atopic Dermatitis, Primary and Secondary Endpoints of Phase II Molecules, Global, 2010 52
Table 9: Endpoints - Clinical Trials in Dermatology, Atopic Dermatitis, Primary and Secondary Endpoints of Discontinued Molecules, Global, 2010 54
Table 10: Endpoints - Clinical Trials in Dermatology, Herpes Zoster, Primary and Secondary Endpoints of Phase III Molecules , Global, 2010 61
Table 11: Endpoints - Clinical Trials in Dermatology, Herpes Zoster, Primary and Secondary Endpoints of Phase II Molecules, Global, 2010 68
Table 12: Endpoints - Clinical Trials in Dermatology, Herpes Zoster, Primary and Secondary Endpoints of Discontinued Molecules, Global, 2010 68
Table 13: Endpoints - Clinical Trials in Dermatology, Acne Vulgaris, Primary and Secondary Endpoints of Phase III Molecules, Global, 2010 81
Table 14: Endpoints - Clinical Trials in Dermatology, Acne Vulgaris, Primary and Secondary Endpoints of Phase II Molecules, Global, 2010 88
Table 15: Endpoints - Clinical Trials in Dermatology, Acne Vulgaris, Primary and Secondary Endpoints of Discontinued Molecules, Global, 2010 89

List of Figures

1.2 List of Figures
Figure 1: Endpoints - Clinical Trials in Dermatology, Alopecia, Phase III Clinical Trials by Primary Endpoints, Global, 2010 14
Figure 2: Endpoints - Clinical Trials in Dermatology, Alopecia, Phase III Clinical Trials by Multiple Primary Endpoints, Global, 2010 14
Figure 3: Endpoints - Clinical Trials in Dermatology, Alopecia, Phase III Clinical Trials by Secondary Endpoints, Global, 2010 15
Figure 4: Endpoints - Clinical Trials in Dermatology, Alopecia, Phase III Clinical Trials by Multiple Secondary Endpoints, Global, 2010 15
Figure 5: Endpoints - Clinical Trials in Dermatology, Alopecia, Phase II Clinical Trials by Multiple Primary Endpoints, Global, 2010 17
Figure 6: Endpoints - Clinical Trials in Dermatology, Alopecia, Phase II Clinical Trials by Multiple Secondary Endpoints, Global, 2010 18
Figure 7: Endpoints - Clinical Trials in Dermatology, Candidiasis, Phase III Clinical Trials by Primary Endpoints, Global, 2010 28
Figure 8: Endpoints - Clinical Trials in Dermatology, Candidiasis, Phase III Clinical Trials by Multiple Primary Endpoints, Global, 2010 28
Figure 9: Endpoints - Clinical Trials in Dermatology, Candidiasis, Phase III Clinical Trials by Secondary Endpoints, Global, 2010 29
Figure 10: Endpoints - Clinical Trials in Dermatology, Candidiasis, Phase III Clinical Trials by Multiple Secondary Endpoints, Global, 2010 30
Figure 11: Endpoints - Clinical Trials in Dermatology, Candidiasis, Phase II Clinical Trials by Primary Endpoints, Global, 2010 34
Figure 12: Endpoints - Clinical Trials in Dermatology, Candidiasis, Phase II Clinical Trials by Secondary Endpoints, Global, 2010 34
Figure 13: Endpoints - Clinical Trials in Dermatology, Candidiasis, Phase II Clinical Trials by Multiple Secondary Endpoints, Global, 2010 35
Figure 14: Endpoints - Clinical Trials in Dermatology, Atopic Dermatitis, Phase III Clinical Trials by Primary Endpoints, Global, 2010 42
Figure 15: Endpoints - Clinical Trials in Dermatology, Atopic Dermatitis, Phase III Clinical Trials by Multiple Primary Endpoints, Global, 2010 43
Figure 16: Endpoints - Clinical Trials in Dermatology, Atopic Dermatitis, Phase III Clinical Trials by Secondary Endpoints, Global, 2010 43
Figure 17: Endpoints - Clinical Trials in Dermatology, Atopic Dermatitis, Phase III Clinical Trials by Multiple Secondary Endpoints, Global, 2010 44
Figure 18: Endpoints - Clinical Trials in Dermatology, Atopic Dermatitis, Phase II Clinical Trials by Primary Endpoints, Global, 2010 48
Figure 19: Endpoints - Clinical Trials in Dermatology, Atopic Dermatitis, Phase II Clinical Trials by Multiple Primary Endpoints, Global, 2010 49
Figure 20: Endpoints - Clinical Trials in Dermatology, Atopic Dermatitis, Phase II Clinical Trials by Secondary Endpoints, Global, 2010 50
Figure 21: Endpoints - Clinical Trials in Dermatology, Atopic Dermatitis, Phase II Clinical Trials by Multiple Secondary Endpoints, Global, 2010 51
Figure 22: Endpoints - Clinical Trials in Dermatology, Herpes Zoster, Phase III Clinical Trials by Primary Endpoints, Global, 2010 58
Figure 23: Endpoints - Clinical Trials in Dermatology, Herpes Zoster, Phase III Clinical Trials by Multiple Primary Endpoints, Global, 2010 59
Figure 24: Endpoints - Clinical Trials in Dermatology, Herpes Zoster, Phase III Clinical Trials by Secondary Endpoints, Global, 2010 60
Figure 25: Endpoints - Clinical Trials in Dermatology, Herpes Zoster, Phase III Clinical Trials by Multiple Secondary Endpoints, Global, 2010 60
Figure 26: Endpoints - Clinical Trials in Dermatology, Herpes Zoster, Phase II Clinical Trials by Primary Endpoints, Global, 2010 64
Figure 27: Endpoints - Clinical Trials in Dermatology, Herpes Zoster, Phase II Clinical Trials by Multiple Primary Endpoints, Global, 2010 65
Figure 28: Endpoints - Clinical Trials in Dermatology, Herpes Zoster, Phase II Clinical Trials by Secondary Endpoints, Global, 2010 66
Figure 29: Endpoints - Clinical Trials in Dermatology, Herpes Zoster, Phase II Clinical Trials by Multiple Secondary Endpoints, Global, 2010 67
Figure 30: Endpoints - Clinical Trials in Dermatology, Acne Vulgaris, Phase III Clinical Trials by Primary Endpoints, Global, 2010 77
Figure 31: Endpoints - Clinical Trials in Dermatology, Acne Vulgaris, Phase III Clinical Trials by Multiple Primary Endpoints, Global, 2010 78
Figure 32: Endpoints - Clinical Trials in Dermatology, Acne Vulgaris, Phase III Clinical Trials by Secondary Endpoints, Global, 2010 79
Figure 33: Endpoints - Clinical Trials in Dermatology, Acne Vulgaris, Phase III Clinical Trials by Multiple Secondary Endpoints, Global, 2010 80
Figure 34: Endpoints - Clinical Trials in Dermatology, Acne Vulgaris, Phase II Clinical Trials by Primary Endpoints, Global, 2010 84
Figure 35: Endpoints - Clinical Trials in Dermatology, Acne Vulgaris, Phase II Clinical Trials by Multiple Primary Endpoints, Global, 2010 85
Figure 36: Endpoints - Clinical Trials in Dermatology, Acne Vulgaris, Phase II Clinical Trials by Secondary Endpoints, Global, 2010 86
Figure 37: Endpoints - Clinical Trials in Dermatology, Acne Vulgaris, Phase II Clinical Trials by Multiple Secondary Endpoints, Global, 2010 87

Companies Mentioned

Merck
Novartis
GlaxoSmithKline
Pfizer
Astellas Pharma
Galderma

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Regulatory Affairs Outsourcing Market (Services: Regulatory Affairs, Clinical Trial Applications and Product Registrations, Regulatory Writing and Publishing, Regulatory Consulting and Legal Representation and Others) - Global Industry Analysis, Size, Sha

Regulatory Affairs Outsourcing Market (Services: Regulatory Affairs, Clinical Trial Applications and Product Registrations, Regulatory Writing and Publishing, Regulatory Consulting and Legal Representation and Others) - Global Industry Analysis, Size, Sha

  • $ 4 795
  • Industry report
  • October 2014
  • by Transparency Market Research

This report on the regulatory affairs outsourcing market studies the current as well as future prospects of the market globally. Regulatory affairs outsourcing is rapidly gaining popularity in the global ...

Proteomics Markets for Research and IVD Applications

Proteomics Markets for Research and IVD Applications

  • $ 4 200
  • Industry report
  • September 2014
  • by Kalorama Information

This Kalorama Information report defines markets and identifies trends for proteomics applications, both in their research use and in IVD. Proteomics is the study of proteins, including the study of the ...

Biologicals in Oncology Drug Pipeline Update 2014

Biologicals in Oncology Drug Pipeline Update 2014

  • $ 3 749
  • Industry report
  • October 2014
  • by Bioseeker

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 908 companies plus partners developing 1784 biological ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.